News - Pricing, Global


Current filters:


Popular Filters

1 to 25 of 28 results

GSK commits to five-year vaccine price freeze for countries graduating from GAVI Alliance support


UK pharma giant GlaxoSmithKline has said it will freeze the prices of its vaccines for a period of five…


ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay


Viiv Healthcare, the HIV/AIDS joint venture of UK pharma giant GlaxoSmithKline, US drugmaker Pfizer and…

Anti-viralsGlobalPharmaceuticalPricingTivicayViiV Healthcare

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management


As health care budgets are squeezed worldwide and access issues continue to make the headlines, the price…


Sanofi Pasteur wins order for IPV from UNICEF, cutting price to $1 per dose


Sanofi Pasteur, the vaccines division of French drug major Sanofi, says that UNICEF, the organization…

GlobalMarkets & MarketingPharmaceuticalPricingSanofiSanofi PasteurVaccines

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries


US biotech Gilead Sciences has indicated it would charge $2,000 per 24 week treatment course for the…

Anti-viralsBiotechnologyGilead SciencesGlobalIndiaPricingsofosbuvirSovaldi

Lack understanding of the impact of global drug pricing on profits, finds Model N survey


More than half (58%) of pharmaceutical companies believe the challenges of global drug pricing are not…


MSF calls for urgent action on vaccines to save lives

MSF calls for urgent action on vaccines to save lives


Humanitarian medical organization Medecins Sans Frontieres is calling for four key policy changes to…


UNITAID helps accessing quality drugs at affordable prices


At an interactive session with Indian pharmaceuticals and diagnostics industry leaders organized by the…


Aid group urges countries not to trade away health as TPP negotiations intensify


The far-reaching Trans-Pacific Partnership Agreement (TPP) should be a force for improving health outcomes…


In wake of Tivicay approval, MSF asks, "when will people in developing countries have access?"


As the US Food and Drug Administration approved the new HIV drug Tivicay (dolutegravir) late Monday (The…

Anti-viralsdolutegravirGlobalHealthcarePharmaceuticalPricingTivicayViiV Healthcare

GAVI Alliance gets reduced price offers from Pfizer and GSK


The price that the GAVI Alliance, a public/private partnership, pays for lifesaving pneumococcal vaccines…


UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products


UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

Launching new drugs in the Outcome Era; report


The pharmaceutical industry is facing the Outcome Era. Launching a novel drug today obliges companies…

GlobalMarkets & MarketingPharmaceuticalPricingRegulation

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData


The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review


Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

Big Pharma doing more for access to medicine in developing countries than two years ago


The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts…

AstraZenecaBayerGlaxoSmithKlineGlobalHealthcareJohnson & JohnsonMerck KGaAPharmaceuticalPricingResearch

Confidential pricing agreements mitigate risks of low drug prices in key markets


Pharmaceutical brand teams design their global launch sequencing strategies to mitigate the risks associated…


Reference pricing increases as a major consideration in strategic plans for pharmaceutical launch sequencing


Pharmaceutical brand teams eager to maximize the price of the drugs establish intricate product launch…

GlobalMarkets & MarketingPharmaceuticalPricing

A blip or stark reality? Pharma companies re-evaluate emerging markets


Pharmaceutical companies, which have previously been allaying the growing fears and concerns of their…

FinancialGlobalMarkets & MarketingPharmaceuticalPricingRegulation

Middle-income countries flex muscles to overcome patents in face of unaffordable drug prices


Middle-income countries are increasingly taking measures to overcome the patents that price drugs out…


Current pharma pricing policy will hurt both patients and industry in the long run, assert pharma experts


Pharmaceutical analysts in India and the UK believe cost-based pricing is not suitable to safeguard the…


Global generic drug markets will grow to $221 billion by 2016; Espicom


The economic recession has been a double-edged sword for the international generic drugs business. Driven…

GenericsGlobalMarkets & MarketingMergers & AcquisitionsPricing

1 to 25 of 28 results

Back to top